Analysis of the CCL3-L1 gene for association with HIV-1 susceptibility and disease progression

AIDS

Volumn 18, Issue 7, 2004, Pages 1069-1071

  Bugeja, Matthew J ^a   Booth, David R ^a   Bennetts, Bruce H ^b   Guerin, Jan ^c   Kaldor, John M ^c   Stewart, Graeme J ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE CCL3 L1; CHEMOKINE RECEPTOR CCR5; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; FREQUENCY ANALYSIS; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEREDITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; MACROPHAGE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BINDING; T LYMPHOCYTE; VIRUS INHIBITION;

DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; MALE;

EID: 2342510411     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200404300-00017     Document Type: Article

References (21)

1. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-377.
2. Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 2001; 135:782-795.
3. Stewart GJ, Ashton LJ, Biti RA, Ffrench RA, Bennetts BH, Newcombe NR, et al. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. AIDS 1997; 11:1833-1838.
4. Biti R, Ffrench R, Young J, Bennetts B, Stewart G, Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997; 3:252-253.
5. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-673.
6. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997; 277:959-965.
7. Stewart C. Chemokine genes - beating the odds. Nat Med 1998; 4:275-277.
8. Clegg AO, Ashton LJ, Biti RA, Badhwar P, Williamson P, Kaldor JM, et al. CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. The Australian Long-Term Non-Progressor Study Group. AIDS 2000; 14:103-108.
9. Furci L, Scarlatti G, Burastero S, Tambussi G, Colognesi C, Quillent C, et al. Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med 1997; 186:455-460.
10. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, VanDevanter NL, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996; 2:412-417.
11. Saha K, Bentsman C, Chess L, Volsky DJ. Endogenous production of beta-chemokines by CD4+, but not CD8+, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. J Virol 1998; 72:876-881.
12. Menten P, Struyf S, Schutyser E, Wuyts A, De Clercq E, Schols D, et al. The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine. J Clin Invest 1999; 104:R1-R5.
13. Xin X, Shioda T, Kato A, Liu H, Sakai Y, Nagai Y. Enhanced anti-HIV-1 activity of CC-chemokine LD78beta, a non-allelic variant of MIP-1alpha/ LD78alpha. FEBS Lett 1999; 457:219-222.
14. Nakao M, Nomiyama H, Shimada K. Structures of human genes coding for cytokine LD78 and their expression. Mol Cell Biol 1990; 10:3646-3658.
15. Townson JR, Barcellos LF, Nibbs RJ. Gene copy number regulates the production of the human chemokine CCL3-L1. Eur J Immunol 2002; 32:3016-3026.
16. Kuklin A, Munson K, Gjerde D, Haefele R, Taylor P. Detection of single-nucleotide polymorphisms with the WAVE DNA fragment analysis system. Genet Test 1997; 1:201-206.
17. Cameron MJ, Arreaza GA, Grattan M, Meagher C, Sharif S, Burdick MD, et al. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J Immunol 2000; 165:1102-1110.
18. Cook DN, Beck MA, Coffman TM, Kirby SL, Sheridan JF, Pragnell IB, et al. Requirement of MIP-1 alpha for an inflammatory response to viral infection. Science 1995; 269:1583-1585.
19. McMahon EJ, Cook DN, Suzuki K, Matsushima GK. Absence of macrophage-inflammatory protein-1 alpha delays central nervous system demyelination in the presence of an intact blood-brain barrier. J Immunol 2001; 167:2964-2971.
20. Scala E, D'Offizi G, Rosso R, Turriziani O, Ferrara R, Mazzone AM, et al. C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J Immunol 1997; 158:4485-4492.
21. Ullum H, Cozzi Lepri A, Victor J, Aladdin H, Phillips AN, Gerstoft J, et al. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1beta are associated with a decreased risk of HIV disease progression. J Infect Dis 1998; 177:331-336.